Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: SELL (auto-tracking)
-0.61% $18.41
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 517.58 mill |
EPS: | -1.536 |
P/E: | -11.99 |
Earnings Date: | Aug 09, 2022 |
SharesOutstanding: | 28.11 mill |
Avg Daily Volume: | 0.230 mill |
RATING 2024-04-19 |
---|
A+ |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Strong Buy | |
P/E: | Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -11.99 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.25x |
Company: PE -11.99 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 17.46 - 19.36 ( +/- 5.15%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Kelley Erika K. | Buy | 0 | |
2024-02-20 | Minor Glenda J | Buy | 95 | Class A Common Stock |
2024-02-20 | Sutherlin Michael W | Buy | 406 | Class A Common Stock |
2024-02-20 | Shoemaker Leslie L | Buy | 43 | Class A Common Stock |
2024-02-20 | Jahnke David L | Buy | 515 | Class A Common Stock |
INSIDER POWER |
---|
-78.77 |
Last 94 transactions |
Buy: 7 552 389 | Sell: 18 343 130 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $18.41 (-0.61% ) |
Volume | 0.218 mill |
Avg. Vol. | 0.230 mill |
% of Avg. Vol | 94.84 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $24.47 | N/A | Active |
---|
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.